(Q33785405)

29 July 2017

1 reference

title

Aromatase inhibitors in the treatment of postmenopausal breast cancer (English)

1 reference

29 July 2017

Bajetta E

1

1 reference

29 July 2017

Zilembo N

series ordinal

2

1 reference

29 July 2017

Bichisao E

series ordinal

3

1 reference

29 July 2017

publication date

1 October 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

15

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

271-283

1 reference

Aromatase inhibitors in metastatic breast cancer.

29 July 2017

cites work

1 reference

12 December 2020

Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers

1 reference

12 December 2020

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang

1 reference

12 December 2020

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer

1 reference

12 December 2020

A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: Endocrine and clinical results

1 reference

12 December 2020

An in vivo model of intratumoural aromatase using aromatase‐transfected MCF7 human breast cancer cells

1 reference

12 December 2020

A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene

1 reference

12 December 2020

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

12 December 2020

1 reference

12 December 2020

Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model

1 reference

12 December 2020

Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione

1 reference

12 December 2020

Aromatase inhibitors and breast cancer

1 reference

12 December 2020

Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer

1 reference

12 December 2020

Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group

1 reference

12 December 2020

Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer

1 reference

12 December 2020

The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer

1 reference

12 December 2020

Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues

1 reference

12 December 2020

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report

1 reference

12 December 2020

Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects

1 reference

12 December 2020

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

12 December 2020

Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?

1 reference

12 December 2020

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

12 December 2020

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer

1 reference

12 December 2020

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

1 reference

12 December 2020

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

1 reference

12 December 2020

Oestradiol synthesis from C19 steroids by human breast cancers

1 reference

12 December 2020

The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11

1 reference

12 December 2020

The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer

1 reference

12 December 2020

The control and biological importance of intratumoural aromatase in breast cancer

1 reference

12 December 2020

Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor

1 reference

12 December 2020

ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

1 reference

12 December 2020

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route

1 reference

12 December 2020

The importance of local synthesis of estrogen within the breast

1 reference

12 December 2020

Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole

1 reference

12 December 2020

Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer

1 reference

12 December 2020

4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer

1 reference

12 December 2020

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

12 December 2020

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study

1 reference

12 December 2020

New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity

1 reference

12 December 2020

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression

1 reference

12 December 2020

10.2165/00002512-199915040-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1045339984

0 references

1 reference